Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline Post ContentvstmRead More You might also be interested in reading LMAX eyes $5B Nasdaq IPO as sale talks gather pace. August 8, 2025 In Mainstream ← Previous post Next post →